{"id":134556,"date":"2026-07-24T09:34:03","date_gmt":"2026-07-24T09:34:03","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/134556\/"},"modified":"2026-07-24T09:34:03","modified_gmt":"2026-07-24T09:34:03","slug":"novo-nordisk-moves-to-block-rival-eli-lillys-drug-advertisements-in-u-s-court","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/134556\/","title":{"rendered":"Novo Nordisk Moves to Block Rival Eli Lilly&#8217;s Drug Advertisements in U.S. Court"},"content":{"rendered":"<p>In a significant legal maneuver, Novo Nordisk has filed for a preliminary U.S. court injunction aiming to block advertisements by Eli Lilly. This move marks a heightened escalation in the competition between the two pharmaceutical giants over the lucrative market for obesity treatments.<\/p>\n<p>The Danish company argued that Lilly&#8217;s advertisements mislead consumers by comparing lower doses of Novo&#8217;s medicines with the highest approved doses of Lilly&#8217;s Zepbound and Mounjaro products. Novo has called for a permanent injunction and corrective advertising, claiming that this creates a perception of superiority for Lilly&#8217;s offerings.<\/p>\n<p>As the legal battle unfolds, analysts watch closely, with the obesity drug market in the U.S. anticipated to exceed $100 billion by the decade&#8217;s end. Lilly, for its part, has denied any wrongdoing and is preparing to robustly defend its advertising practices in court.<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"In a significant legal maneuver, Novo Nordisk has filed for a preliminary U.S. court injunction aiming to block&hellip;\n","protected":false},"author":2,"featured_media":134557,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[65279,13009,14737,276,64655,20191,272,9754,65280,65278],"class_list":["post-134556","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-advertising-dispute","tag-diabetes-treatments","tag-drug-market","tag-eli-lilly","tag-false-advertising","tag-legal-battle","tag-novo-nordisk","tag-obesity-drugs","tag-pharmaceutical-rivalry","tag-u-s-court"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116974273591858751","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/134556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=134556"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/134556\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/134557"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=134556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=134556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=134556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}